Deparment of Cancer Imaging and Metabolism
Moffitt Cancer Center
United States of America
Dr. Natarajan Raghunand is affiliated to Deparment of Cancer Imaging and Metabolism, Moffitt Cancer Center. Dr. Natarajan Raghunand is currently providing services as Researcher. Dr. Natarajan Raghunand has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Natarajan Raghunand contributions have acclaimed recognition from honourable subject experts around the world. Dr. Natarajan Raghunand is actively associated with different societies and academies. Dr. Natarajan Raghunand academic career is decorated with several reputed awards and funding. Dr. Natarajan Raghunand research interests include Dr. Raghunand's research focus is in developing non-invasive imaging biomarkers that enable the individualized selection of therpeutic regimens..
Dr. Raghunand's research focus is in developing non-invasive imaging biomarkers that enable the individualized selection of therpeutic regimens.
Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clinical Cancer Research. 2016 Jun 15;22(12):2848-54.
Ramanathan RK, Korn R, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J. Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study. Clinical Cancer Research. 2017 Jan 1:clincanres-1990.
Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget. 2017 Jun 12.